Suven Life Sciences Share Price Target 2026 Analyst Forecast Bull and Bear Case

Suven Life Sciences (NSE: SUVEN) is a Pharmaceutical CDMO and Specialty Chemicals company trading at Rs 258.3 with a market capitalisation of Rs 3,274 crore. Analysts have set the Suven Life Sciences share price target at Rs 310 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Suven Life Sciences Share Price Target 2026: Key Takeaways

• Suven Life Sciences share price target 2026: Rs 310 (20% upside from CMP Rs 258.3)
• Bull case: Rs 375 | Bear case: Rs 205
• Ticker: SUVEN | Sector: Pharmaceutical CDMO and Specialty Chemicals | MCap: Rs 3,274 crore
• 52W range: Rs 179 to Rs 424 | PE: 20x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Suven Life Sciences Company Overview

Suven Life Sciences (NSE: SUVEN) is a Hyderabad-based pharmaceutical CDMO company providing contract research, process chemistry, and API manufacturing services to global innovator pharma companies. At CMP Rs 258.3 against a 52 week range of Rs 179 to Rs 424, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 3,274 crore with trailing PE of 20x. Compared to peers in CDMO like Divi’s Laboratories and Anthem Biosciences, Suven Life Sciences is positioned as a potential re-rating candidate toward the Rs 310 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	SUVEN
Sector	Pharmaceutical CDMO and Specialty Chemicals
CMP (2026)	Rs 258.3
52 Week High	Rs 424
52 Week Low	Rs 179
Market Cap	Rs 3,274 crore
Trailing PE	20x
12-Month Analyst Target	Rs 310
Bull Case Target	Rs 375
Bear Case Target	Rs 205

Why Is the Suven Life Sciences Share Price Target Set at Rs 310 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Suven Life Sciences share price target of Rs 310 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 258.3.

Structural Sector Tailwinds in Pharmaceutical CDMO and Specialty Chemicals

The Pharmaceutical CDMO and Specialty Chemicals sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Suven Life Sciences’s position among peers in CDMO like Divi’s Laboratories and Anthem Biosciences creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 375 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Suven Life Sciences’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 310 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Suven Life Sciences’s Pharmaceutical CDMO and Specialty Chemicals operations, improving the probability of achieving the Rs 310 price objective through FY27 earnings delivery.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 20x PE, Suven Life Sciences is positioned as a beneficiary of institutional reallocation toward the Rs 375 bull case over the medium term.

Suven Life Sciences Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Suven Life Sciences Share Price Target

Near-term support for Suven Life Sciences is anchored close to the 52 week low of Rs 179. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 258.3.

12-Month Suven Life Sciences Share Price Target 2026

The 12-month Suven Life Sciences share price target 2026 is Rs 310, implying approximately 20 percent upside from CMP Rs 258.3. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.

Long Term Suven Life Sciences Share Price Target: FY27 to FY28

The long term Suven Life Sciences share price target for FY27 to FY28 is Rs 375 in the bull case, requiring full earnings delivery, re-rating among peers in CDMO like Divi’s Laboratories and Anthem Biosciences, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Suven Life Sciences in 2026

Bull Case Suven Life Sciences Share Price Target: Rs 375

The bull case Suven Life Sciences share price target of Rs 375 materialises when FY27 earnings beat analyst estimates, Pharmaceutical CDMO and Specialty Chemicals tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 258.3, this represents approximately 45 percent potential upside.

Bear Case Suven Life Sciences Share Price Target: Rs 205

The bear case Suven Life Sciences share price target of Rs 205 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 179.

Scenario	Target	Key Conditions
Bull Case	Rs 375	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 310	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 205	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Suven Life Sciences 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Suven Life Sciences share price target of Rs 310, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 310 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among Pharmaceutical CDMO and Specialty Chemicals Peers

Intensifying competition from peers in CDMO like Divi’s Laboratories and Anthem Biosciences could compress Suven Life Sciences’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 310 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.

How to Invest in Suven Life Sciences

Check the Univest Screener for live data

Before considering any investment based on the Suven Life Sciences share price target of Rs 310, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical CDMO and Specialty Chemicals sector demand.

Open a Demat account with a SEBI registered stockbroker to trade Suven Life Sciences (NSE: SUVEN) with full regulatory protection. Study the competitive landscape among peers in CDMO like Divi’s Laboratories and Anthem Biosciences before executing any position.

Plan your entry using the 52 week low of Rs 179 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 310 price objective. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Suven Life Sciences’s live share price and receive daily stock recommendations.

FAQs on Suven Life Sciences Share Price Target 2026

What is the Suven Life Sciences share price target for 2026?

Ans. The Suven Life Sciences share price target 2026 is Rs 310, implying approximately 20 percent upside from CMP Rs 258.3. Bull case is Rs 375, bear case is Rs 205.

What was the Suven Life Sciences share price target for 2025?

Ans. The 2025 price objective for Suven Life Sciences was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 310, reflecting FY27 growth potential from CMP Rs 258.3.

Is Suven Life Sciences a good investment at Rs 258.3?

Ans. At Rs 258.3, Suven Life Sciences offers potential upside toward Rs 310 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Suven Life Sciences share price target 2026?

Ans. Key risks to the Suven Life Sciences share price target of Rs 310 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical CDMO and Specialty Chemicals. Monitoring quarterly results is essential.

What is the 52 week high and low of Suven Life Sciences?

Ans. The 52 week high of Suven Life Sciences is Rs 424 and the 52 week low is Rs 179. At CMP Rs 258.3, the stock offers potential upside toward the Rs 310 price objective.

What are the main growth catalysts for Suven Life Sciences in 2026?

Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical CDMO and Specialty Chemicals tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Suven Life Sciences compare to its peers?

Ans. Suven Life Sciences operates in Pharmaceutical CDMO and Specialty Chemicals alongside peers in CDMO like Divi’s Laboratories and Anthem Biosciences. At CMP Rs 258.3 with MCap Rs 3,274 crore, it is a potential re-rating candidate toward the Suven Life Sciences share price target of Rs 310 on FY27 delivery.

What is the Suven Life Sciences share price target for 2027?

Ans. The long-term Suven Life Sciences share price target for FY27 to FY28 is Rs 375 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.